Archives

Exposure-adjusted incidence rates of serious adverse events 8.5 versus 11.2 per 100 patient-years for anifrolumab versus placebo

Authors say immune response similar for patients holding methotrexate for one week or two weeks

Both weight-based and non-weight-based low-dose HCQ associated with increased hospitalizations for SLE

Furthermore, one-third of adults with food allergy think epinephrine auto-injectors can cause life-threatening effects

Survival to hospital discharge higher with use of double sequential external defibrillation compared with standard defibrillation

Risk for progression of kidney disease or death from cardiovascular causes reduced with empagliflozin versus placebo

No difference seen with discontinuation, continuation of RAS inhibitors among patients with advanced, progressive chronic kidney disease

Outcomes better for surgical revascularization versus endovascular therapy for those with single segment of great saphenous vein that could be used for surgery

Dose-dependent reductions in systolic blood pressure seen in phase 2 dose-ranging study

In patients with T2DM, hypertriglyceridemia, and low HDL cholesterol levels, the risk for cardiovascular events was not lower with pemafibrate versus placebo